Empirical Finance LLC raised its holdings in shares of Taro Pharmaceutical Industries Ltd. (NYSE:TARO) by 0.2% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,332 shares of the company’s stock after acquiring an additional 23 shares during the quarter. Empirical Finance LLC’s holdings in Taro Pharmaceutical Industries were worth $1,158,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also bought and sold shares of the business. AJO LP increased its holdings in Taro Pharmaceutical Industries by 73.4% during the 2nd quarter. AJO LP now owns 9,328 shares of the company’s stock valued at $1,045,000 after acquiring an additional 3,948 shares in the last quarter. Alliancebernstein L.P. boosted its stake in shares of Taro Pharmaceutical Industries by 8.5% during the 2nd quarter. Alliancebernstein L.P. now owns 14,538 shares of the company’s stock worth $1,629,000 after purchasing an additional 1,144 shares during the last quarter. Wells Fargo & Company MN boosted its stake in shares of Taro Pharmaceutical Industries by 11.2% during the 2nd quarter. Wells Fargo & Company MN now owns 1,685 shares of the company’s stock worth $189,000 after purchasing an additional 170 shares during the last quarter. Freestone Capital Holdings LLC boosted its stake in shares of Taro Pharmaceutical Industries by 0.3% during the 2nd quarter. Freestone Capital Holdings LLC now owns 142,750 shares of the company’s stock worth $15,996,000 after purchasing an additional 441 shares during the last quarter. Finally, River Road Asset Management LLC boosted its stake in shares of Taro Pharmaceutical Industries by 33.3% during the 2nd quarter. River Road Asset Management LLC now owns 65,470 shares of the company’s stock worth $7,337,000 after purchasing an additional 16,350 shares during the last quarter. Hedge funds and other institutional investors own 14.24% of the company’s stock.

Taro Pharmaceutical Industries Ltd. (TARO) traded up 0.55% during midday trading on Wednesday, hitting $105.01. 5,222 shares of the company’s stock traded hands. Taro Pharmaceutical Industries Ltd. has a 52 week low of $92.28 and a 52 week high of $125.87. The company has a market capitalization of $4.25 billion, a PE ratio of 10.69 and a beta of 0.65. The company has a 50 day moving average of $106.58 and a 200-day moving average of $112.09.

COPYRIGHT VIOLATION NOTICE: “Empirical Finance LLC Acquires 23 Shares of Taro Pharmaceutical Industries Ltd. (TARO)” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another domain, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The correct version of this report can be read at https://www.thecerbatgem.com/2017/09/13/empirical-finance-llc-acquires-23-shares-of-taro-pharmaceutical-industries-ltd-taro.html.

Several research firms have issued reports on TARO. BidaskClub cut shares of Taro Pharmaceutical Industries from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. TheStreet cut shares of Taro Pharmaceutical Industries from a “b-” rating to a “c+” rating in a research note on Wednesday, August 9th. Finally, Credit Suisse Group cut shares of Taro Pharmaceutical Industries from an “outperform” rating to a “neutral” rating in a research note on Tuesday, May 23rd.

About Taro Pharmaceutical Industries

Taro Pharmaceutical Industries Ltd. (Taro) is a science-based pharmaceutical company. The Company operates principally through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc (Taro Canada) and Taro U.SA The Company markets over 200 pharmaceutical products in over 25 countries.

Institutional Ownership by Quarter for Taro Pharmaceutical Industries (NYSE:TARO)

Receive News & Stock Ratings for Taro Pharmaceutical Industries Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries Ltd. and related stocks with our FREE daily email newsletter.